NCT01589653 - Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

May 26, 2012

Primary Completion Date

July 9, 2015

Study Completion Date

July 9, 2015

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.

DRUG

biphasic insulin aspart 30

Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.

Trial Locations (15)

1007

Novo Nordisk Investigational Site, Tunis

1008

Novo Nordisk Investigational Site, Tunis

11211

Novo Nordisk Investigational Site, Riyadh

11426

Novo Nordisk Investigational Site, Riyadh

11562

Novo Nordisk Investigational Site, Cairo

20100

Novo Nordisk Investigational Site, Casablanca

21131

Novo Nordisk Investigational Site, Alexandria

21944

Novo Nordisk Investigational Site, Ta'if

40000

Novo Nordisk Investigational Site, Marrakesh

40161

Novo Nordisk Investigational Site, Bandung

62511

Novo Nordisk Investigational Site, Banī Suwayf

65111

Novo Nordisk Investigational Site, Malang

80215

Novo Nordisk Investigational Site, Jeddah

Unknown

Novo Nordisk Investigational Site, Hà Nội

Novo Nordisk Investigational Site, Ho Chi Minh City